Abstract
Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the management of lymphoid malignancies. However, it is still in its early phase and is facing many obstacles in solid tumors. Therapeutic challenges in solid tumor lead to tumor target diversification and drive new innovations for the improvement of clinical efficacy. This review showcases early clinical works and sheds light on the most notable successes, drawbacks, and strategies employed to allow CAR T therapy to go full speed ahead.
Recommended Citation
Hsu, Jingmei; Yang, Yang; Gergis, Mia; Bi, Xia; Yi, Dongni; and Gergis, Usama
(2022)
"Chimeric antigen receptor T cell therapy for solid tumors,"
Hematology/Oncology and Stem Cell Therapy: Vol. 15
:
Iss.
3
, Article 9.
Available at: https://doi.org/10.56875/2589-0646.1028
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Included in
Cancer Biology Commons, Hematology Commons, Oncology Commons
